Based on our previous identification of a disubstituted aminothiazole termed HBF-0079 with promising selective toxicity for HCC-derived cell lines versus non-HCC liver lines, a series of tri-substituted aminothiazole derivatives were prepared and evaluated. This work resulted in the discovery of isopropyl 4-(pyrazin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate, 14, which displayed EC 50 value of 0.11 lM and more than 450 times of selectivity, and its methyl carbonate prodrug 24 with improved solubility in organic solvents. Furthermore, 14, was shown to reduce the proliferation of several liver cancer cells derived directly from patients.
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Primary cancer of the liver is a growing problem in the United States and the world. The most common adult primary liver cancer is hepatocellular carcinoma (HCC). This extremely deadly disease is currently one of the fastest growing cancers in incidence in the US. 1 It is the 5 th most common cause of cancer in men and the 7 th most common cause for cancer in women. 2 Primary liver cancer occurs predominantly in patients with liver cirrhosis, which can result from a variety of conditions that irritate the liver, such as chronic hepatitis C, hepatitis B, 3 or excessive alcohol consumption. 4 HCC is traditionally treated by surgery or interventional ablative treatment. 5 However, due to the lack of biomarkers that detect tumors that are at an early enough stage, most patients are diagnosed when surgical resection is no longer feasible. Therefore, chemotherapy remains an important and necessary option for the treatment of inoperable HCC patients. There appears to be a diversity of molecular mechanisms underlying HCC development and maintenance. Microarray and proteomic studies have borne out evidence for molecular heterogeneity. 6, 7 Based on the expression of specific genes, phenotypically identical tumors can be divided into six distinct profiles that correlate with different prognostic outcomes. 8, 9 This heterogeneity suggests that a diversity of pathways are responsible for the establishment and progression of HCC tumors, requiring the structurally diverse anti-liver drugs with different action mechanisms. The current standard of care for patients with advanced forms of liver cancer is oral therapy with a multikinase inhibitor, Sorafenib. 10 This is the only anti-HCC drug approved by FDA and can improve median overall survival by approximately 3 months, 11 but its toxicity in normal liver cells has remained a concern because it is enacting an additional burden on the already diseased liver.
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In this report we describe our continued efforts toward the discovery of substituted aminothiazoles which are potent inhibitors of HCC and hepatoblastoma derived cells but are well tolerated by most other cancer-derived cell lines, as well as non-hepatic cell lines derived from non-cancerous tissue. There are only a handful of small molecules that have been reported to possess selective toxicity to liver cancer versus normal liver cells, making the aminothiazoles described here unusual. [13] [14] [15] [16] [17] [18] [19] Moreover, none of the other liver cancer-selective small molecules have been further progressed, to our knowledge. These compounds are mainly phenolic or flavonoid natural products which were isolated from herbs. [14] [15] [16] [17] Using an orthogonal phenotypic screen, 20 HBF-0079, which exhibits moderate micro-molar potency but remarkable selective toxicity for HCC-derived Huh7 cell lines but not non-HCC liver THLE-2 and PH5CH cell lines. It is also not toxic for most other cancer lines, further demonstrating it specificity for HCC. In addition, in an initial small set of structural alterations, we discovered that IHVR-04042 which possesses the incorporation of an ethyl ester substitution in the central thiazole ring of HBF-079, demonstrated a five-fold increased potency and five-to seven-fold increased selectivity (Fig. 1) . 13 Therefore, more substituted aminothiazoles were synthesized and evaluated in vitro and ex vivo with a goal of increasing or maintaining potency and selectivity, and demonstrating efficacy in the real human HCC tissues.
IHVR-04042 has a relatively flat/conjugated structure, centered by a thiazole with a pyridine substituted at 4-position and pyrimidine at 2-position connected via an amino linker. We began by evaluation of the replacement for ethyl ester group in the central thiazole ring of the IHVR-04042 and effect of an additional CH 2 between amino linker and right pyridine ring (Table 1) . When the CH 2 was inserted, all the resulting compounds, 1, 3, 5, 7 regardless of what types of substitutions at 5-position of the central thiazole ring, lost specific toxicities to the Huh7 cells (CC 50 >40 lM and selectivities <2). Removal of the carbonyl group from the ester in IHVR-04042 provided 2 with a non-conjugated ether substitution, which displayed more than 10-fold weaker toxicity to Huh7 cells; when a bulky isopropyl ester was introduced, a 2-fold decrease in toxicity to Huh7 was observed while it was still selective to THLE2 and PH5CH cells with selectivities of 123.39 and 122.87 respectively; Insertion of one or two CH 2 s between the carbonyl group and thiazole ring led to compound 6 and 8 with flexible pendant groups at 5-position of the thiazole, which exhibited 7-or 10-fold reduction of toxicity to Huh7 cells. Hydrolysis of the ester from compound 8 into acid yielded 9, which further reduced the toxicity to the Huh7 cells. These results indicated that both ester at 5-position and pyrimidine to the amino linker were better to be connected directly.
We next turned our attention to the pyridine at 4-position (Table 2 ) by replacing it with four other bioisosteres either with lower cLogP and basicity (compound 10-11), lower basicity (compound 12) or with a methyl group to increase the steric interaction with the ester group at 5-position of the thiazole so that to change the dihedral angle between pyridine and thiazole rings (compound 13). 21 Interestingly, the position of an additional nitrogen to the pyridine ring resulted in different outcome. Pyrazine 10 is more potent than pyrimidine 11 despite both were less potent than IHVR-04042. Compound 12 with trifluoro substitution at paraposition retained the potency to Huh7 but was more toxic to normal liver cells in THLE2 and PHCH. Incorporation of the methyl group at 5-position of the pyridine significantly decreased the potency suggesting this change is not favored. As discussed above, isopropyl ester and several pyridine replacements can be tolerated at 5-and 4-positions of the thiazole moiety. We then assessed the combination of these two structural alterations (Table 3) . It turned out when pyrazine was partnered with isopropyl ester, the resulting compound 14 demonstrated nearly 2-fold potency and selectivity increases while the two pyrimidine analogs, 15 and 16, had similar potencies and selectivities as their ethyl ester analog 11.
When treated with liver microsomes, 14 displayed a slightly improved stability in human liver microsomes, but more liability in mouse liver microsomes (Table 4) . Detailed MetID analysis revealed that the hydrolysis of the ester and oxidation of the pyridine ring in IHVR-04042 were the major metabolisms that occurred. While for 14, the oxidation of pyridine was avoided due to the replacement with a pyrazine, however, the hydrolysis remained and oxidation of amino pyrimidine became significant (Fig. 2) . The pharmacokinetics of 14 was investigated in mice and compared to IHVR-04042 (Table 5) . Oral (po) bioavailability of 14 was 15%, a little bit higher than that of IHVR-04042 (10%). It is noteworthy that 14 had a high distribution volume (3.49 L/kg), indicating high propensity of tissue distribution. This was proved by the detection of 14 (33.0 ± 18.5 ng/g) in the liver after oral administration in Male CD-1 Mice (Table 5 ). This property should allow more active compound deposit in the liver and be beneficial for liver oriented diseases.
The compounds to date had been tested only with stable tissue culture lines which may not accurately reflect the behavior of primary cells derived directly from the organ. Therefore, having identified a more potent and selective lead compound, we decided to determine if this compound could reduce the proliferation of liver cancer cells derived directly from patients. Thus, compound 14, which exhibited excellent selectivity for HCC derived cells in culture, was used to treat HCC tissues, ex vivo, from 16 patients. Surgically-resected fresh HCC tissues were sectioned into 300 lmthick slices and cultured with compound 14 at 1 lM for 48 h with media change every 24 h, and compared to DMSO-treated control. The anti-tumor effect was assessed by the percentage (%) change of cell proliferation measured by Ki-67 immunostaining-positive cells calculated as an average of randomly chosen 5 high-power fields (Abcam). Among the tested patients, 5 patients showed reduction of the staining (i.e., response rate of 38%) as shown in Figure 3 together with representative Ki-67 staining comparing the drugtreated with control tissues (each patient is denoted by anonymous ev [ex vivo] number). It is not clear why only 38% of the tumors yielded 14 sensitive proliferation, but it is not unusual for explants to behave heterogeneously to drugs. Effort is under way, in other work, to determine if expression and genetic analysis of the sensitive and resistant cultures can reveal clues.
Despite the increased potency and selectivity, similar to IHVR-04042, compound 14 had poor solubility in most of the organic solvents and water (6.35 lM at PH 4 and 5.20 lM at PH 7.4, Table 4 ).
This prompted us to explore prodrug approach to get this molecule into a solution. 22 Based on the structure of our lead compound 14, the amino linker was selected to attach three prodrug moieties for assessment, including methyl phosphate, 23 methyl carbonate 24 and methyl ether, which can change the physical chemical property of the parent compound and have been used to enhance the solubility of some insoluble compounds ( Table 6 ). As expected, all four prodrugs now can be easily dissolved in some organic solvents, such as methylene chloride, ethyl acetate, ethanol, and this improvement can greatly facilitate the preparation of higher concentration formulation. Di-tert-butyl methyl phosphate is an interesting prodrug carrier. In ester form, it can help to improve solubility in organic solvents; while it is hydrolyzed to acid form, it can increase the solubility in water. Incorporation of this moiety to compound 4 yielded compound 21, which retained potency and selectivity; On the contrary, when this group was added to 14 to have 22, the potency dropped for about 9-fold. The difference may be attributed to inefficient hydrolysis to release the parent 14. This may explain why prodrug 23 did not show any selectivity when a more difficult to remove methyl ether was used. However, when methyl carbonate was used to modify the compound 14, the resulting prodrug 24 exhibited an even slightly better potency and selectivity than the parent compound 14, indicating a better permeability was achieved. Thus, through this round of selection, two prodrug moieties were found that could either retain or increase the potency and selectivity of the parent compounds. Compound 24 offered improvements in potency, selectivity, and solubility in organic solvents. Therefore, it was chosen for further studies, for which data will be reported in due course. The synthesis of this novel series of substituted amino thiazoles was achieved through condensation of a thiourea with a bromoketone. This route is efficient and versatile in that it allows us to introduce different substitution groups for evaluation. As exemplified for the synthesis of 14 (Scheme 1), nucleophilic substitution of isopropyl acetate to methyl pyrazine-2-carboxylate 25 provided a b-keto ester 26, which was brominated at alpha position through the reaction with phenyltrimethylammonium tribromide (PMAT) or bromine to afford a key intermediate 27. The other key intermediate 28 was prepared following a reference method. 25 Condensation between 27 and 28 delivered 14. Further alkylation of 14 with chloromethyl isopropyl carbonate was accomplished under basic condition to form the corresponding prodrug 24. Detailed synthetic information for other intermediates and products can be found in the supporting information. In summary, a series of substituted aminothiazoles were designed. Multiple rounds of the optimization were carried out to improve cell based potency and selectivity. This resulted in the identification of compound 14 with a favorable efficacy in the several human HCC isolates tissues and its prodrug 24 with improved solubility in organic solvents and potential for further development. 
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